Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Temporal changes in BEXSERO® antigen sequence type associated with genetic lineages of Neisseria meningitidis over a 15-year period in Western Australia

The BEXSERO® vaccine which is used to prevent serogroup B disease is composed of four sub-capsular protein antigens supplemented with an outer membrane vesicle.

25-hydroxyvitamin D3 status is associated with developing adaptive and innate immune responses in the first 6 months of life

Vitamin D status in early life has been linked to the risk of allergic disease in multiple observational studies.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically...

Eva

  Eva Age 19. Youth advocate, Youth Advisory Group community member.          I believe that research is an integral part of society and contributes

Meningococcal vaccine provides extra protection for bubs

In 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.

Landmark $26m child health study eyes Wanneroo-Joondalup mums and dads

The Federal Government has joined with the Paul Ramsay Foundation to fund the project, with each pledging $13 million over 10 years.

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.

Primum non nocere (“first do no harm”) with oxygen therapy

Britta Regli-von Ungern-Sternberg AM FAHMS MD, PhD, DEAA, FANZA Chair of Paediatric anaesthesia, University of Western Australia; Consultant